Lumonus, an AI-native oncology workflow platform company, closed a A$25 million Series B led by Aviron Investment Management with continued participation from Oncology Ventures. The funding will expand U.S. go‑to‑market and clinical success teams and advance its products (AI Physician and AI Dosimetry). Lumonus reports its platform has supported clinicians in consulting/prescribing over 280,000 cancer treatments and automated creation of 75,000+ treatment plans across the U.S., Australia, and Europe.
Related articles
Press ReleaseMay 8, 2026
West Enclave Merger Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 13, 2026
May 8, 2026
Press ReleaseMay 8, 2026
Shreya Acquisition Group Announces Closing of $110 Million Initial Public Offering (Including Partial Exercise of Over-Allotment Option)
May 8, 2026
Press ReleaseMay 8, 2026
Con Edison Announces $2 Billion At-The-Market (ATM) Equity Offering Program
May 8, 2026
← Back to all articles
Generated by Yeal